


S65487 sulfate

Cat. No.:	HY-138697A
CAS No.:	2416937-01-2
Molecular Formula:	C ₄₁ H ₄₃ ClN ₆ O ₈ S
Molecular Weight:	815.33
Target:	Bcl-2 Family; Apoptosis
Pathway:	Apoptosis
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 135 mg/mL (165.58 mM; Need ultrasonic)					
	H ₂ O : 1.25 mg/mL (1.53 mM; ultrasonic and warming and heat to 60°C)					
	Preparing Stock Solutions	Solvent	Mass	1 mg	5 mg	10 mg
		Concentration				
		1 mM		1.2265 mL	6.1325 mL	12.2650 mL
5 mM			0.2453 mL	1.2265 mL	2.4530 mL	
10 mM		0.1226 mL	0.6132 mL	1.2265 mL		
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 6.75 mg/mL (8.28 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 6.75 mg/mL (8.28 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 6.75 mg/mL (8.28 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	S65487 (VOB560) sulfate, a potent and selective Bcl-2 inhibitor, is a proagent of S55746. S65487 sulfate is also active on BCL-2 mutations, such as G101V and D103Y. S65487 sulfate has poor affinity with MCL-1, BFL-1 and BCL-XL. S65487 sulfate induces apoptosis and has anticancer activities ^{[1][2]} .
In Vitro	S65487 binds to the BH3 hydrophobic groove of BCL-2. S65487 induces apoptosis in a panel of hematological cancer cell lines and inhibits cell proliferation with IC ₅₀ s in the low nM range ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

S65487 induces complete regression in BCL-2-dependent RS4;11 tumors in vivo after a single IV (intravenous) administration. Strong and persistent tumor regression in xenograft models of lymphoid malignancies in mouse and rat are observed at well tolerated doses following weekly IV administration of S65487 in combination with the MCL-1-specific inhibitor, S64315/MIK665^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Arnaud Le Tiran, et al. Abstract 1276: Identification of S65487/VOB560 as a potent and selective intravenous 2nd-generation BCL-2 inhibitor active in wild-type and clinical mutants resistant to Venetoclax. Cancer Research. July 2021.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA